1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,000 | 12,120 | 03.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 139 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 24.09.24 | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 380 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,849 | -2,53 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,660 | +1,53 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| HALOZYME THERAPEUTICS | 55,50 | -2,67 % | Halozyme Therapeutics, Inc.: Halozyme Reports Full Year 2024 Record Revenue Of $1.015 Billion And Exceeds Its Financial Guidance For Royalty Revenue, Adjusted Ebitda And Non-gaap Diluted Eps | Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million
Fourth Quarter Net Income Increased 60% YOY... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,309 | -7,34 % | Benchmark maintains Hold on AbCellera stock, no price target change | ||
| GLOW LIFETECH | 0,041 | -13,68 % | Glow LifeTech Corp.: Glow Lifetech Provides Commercial Update; Continued Growth Momentum with New Product Launch & National Expansion | Toronto, Ontario--(Newsfile Corp. - February 12, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 249,00 | -2,51 % | Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | XFRA YP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOLINERX LTD. DL-... ► Artikel lesen | |
| AADI BIOSCIENCE | 2,400 | -2,44 % | Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer | Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline
MORRISTOWN, N.J., Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc.... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,510 | -7,36 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates | BURLINGTON, Mass., Feb. 25, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,444 | -11,83 % | Applied Therapeutics Appoints John H. Johnson as Executive Chairman | Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| OVID THERAPEUTICS | 0,498 | -2,35 % | Ovid Therapeutics Aktie: Abwärtsstrudel in Sicht? | Die Ovid Therapeutics Aktie verzeichnete am 1. März 2025 einen erneuten Rückschlag an der Börse. Der Aktienkurs fiel auf 0,53 USD, was einen leichten Tagesverlust von 0,24% bedeutet. Dieser Rückgang... ► Artikel lesen | |
| COCRYSTAL | 1,640 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 | Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged... ► Artikel lesen |
Das Unternehmen SELVITA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,820 Euro und damit +0,93 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.
